These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 26896737

  • 1. Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma.
    Zhang C, An T, Wang D, Wan G, Zhang M, Wang H, Zhang S, Li R, Yang X, Wang Y.
    J Control Release; 2016 Mar 28; 226():193-204. PubMed ID: 26896737
    [Abstract] [Full Text] [Related]

  • 2. pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma.
    Wang Y, Chen H, Liu Y, Wu J, Zhou P, Wang Y, Li R, Yang X, Zhang N.
    Biomaterials; 2013 Sep 28; 34(29):7181-90. PubMed ID: 23791500
    [Abstract] [Full Text] [Related]

  • 3. pH- and redox-responsive nanoparticles composed of charge-reversible pullulan-based shells and disulfide-containing poly(ß-amino ester) cores for co-delivery of a gene and chemotherapeutic agent.
    Zhang S, Wang D, Li Y, Li L, Chen H, Xiong Q, Liu Y, Wang Y.
    Nanotechnology; 2018 Aug 10; 29(32):325101. PubMed ID: 29761789
    [Abstract] [Full Text] [Related]

  • 4. Core-shell nanoparticles based on pullulan and poly(β-amino) ester for hepatoma-targeted codelivery of gene and chemotherapy agent.
    Liu Y, Wang Y, Zhang C, Zhou P, Liu Y, An T, Sun D, Zhang N, Wang Y.
    ACS Appl Mater Interfaces; 2014 Aug 10; 6(21):18712-20. PubMed ID: 25289563
    [Abstract] [Full Text] [Related]

  • 5. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
    Wang Y, Yu H, Zhang D, Wang G, Song W, Liu Y, Ma S, Tang Z, Liu Z, Sakurai K, Chen X.
    Acta Biomater; 2019 Jul 01; 92():229-240. PubMed ID: 31100462
    [Abstract] [Full Text] [Related]

  • 6. Pullulan-coated phospholipid and Pluronic F68 complex nanoparticles for carrying IR780 and paclitaxel to treat hepatocellular carcinoma by combining photothermal therapy/photodynamic therapy and chemotherapy.
    Wang D, Zhang S, Zhang T, Wan G, Chen B, Xiong Q, Zhang J, Zhang W, Wang Y.
    Int J Nanomedicine; 2017 Jul 01; 12():8649-8670. PubMed ID: 29255359
    [Abstract] [Full Text] [Related]

  • 7. pH-responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma.
    Wu M, Zhong C, Zhang Q, Wang L, Wang L, Liu Y, Zhang X, Zhao X.
    J Nanobiotechnology; 2021 Feb 06; 19(1):39. PubMed ID: 33549107
    [Abstract] [Full Text] [Related]

  • 8. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
    Zhang J, Zhang M, Ji J, Fang X, Pan X, Wang Y, Wu C, Chen M.
    Pharm Res; 2015 Oct 06; 32(10):3376-90. PubMed ID: 26148773
    [Abstract] [Full Text] [Related]

  • 9. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Gao DY, Lin TsT, Sung YC, Liu YC, Chiang WH, Chang CC, Liu JY, Chen Y.
    Biomaterials; 2015 Oct 06; 67():194-203. PubMed ID: 26218745
    [Abstract] [Full Text] [Related]

  • 10. Poly(lactic-co-glycolic acid)-loaded nanoparticles of betulinic acid for improved treatment of hepatic cancer: characterization, in vitro and in vivo evaluations.
    Kumar P, Singh AK, Raj V, Rai A, Keshari AK, Kumar D, Maity B, Prakash A, Maiti S, Saha S.
    Int J Nanomedicine; 2018 Oct 06; 13():975-990. PubMed ID: 29497292
    [Abstract] [Full Text] [Related]

  • 11. A supramolecular nanoparticle system based on β-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma.
    Xiong Q, Cui M, Bai Y, Liu Y, Liu D, Song T.
    Colloids Surf B Biointerfaces; 2017 Jul 01; 155():93-103. PubMed ID: 28411478
    [Abstract] [Full Text] [Related]

  • 12. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
    Chen F, Zhang J, He Y, Fang X, Wang Y, Chen M.
    Biomater Sci; 2016 Jan 01; 4(1):167-82. PubMed ID: 26484363
    [Abstract] [Full Text] [Related]

  • 13. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
    Zhao R, Li T, Zheng G, Jiang K, Fan L, Shao J.
    Biomaterials; 2017 Oct 01; 143():1-16. PubMed ID: 28755539
    [Abstract] [Full Text] [Related]

  • 14. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations.
    Shenoy D, Little S, Langer R, Amiji M.
    Mol Pharm; 2005 Oct 01; 2(5):357-66. PubMed ID: 16196488
    [Abstract] [Full Text] [Related]

  • 15. Charge-reversal nanoparticles: novel targeted drug delivery carriers.
    Chen X, Liu L, Jiang C.
    Acta Pharm Sin B; 2016 Jul 01; 6(4):261-7. PubMed ID: 27471667
    [Abstract] [Full Text] [Related]

  • 16. Effect of paclitaxel-loaded nanoparticles on the viability of human hepatocellular carcinoma HepG2 cells.
    Hou ZH, Zhao WC, Zhang Q, Zheng W.
    Asian Pac J Cancer Prev; 2015 Jul 01; 16(5):1725-8. PubMed ID: 25773816
    [Abstract] [Full Text] [Related]

  • 17. Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response.
    Tran BN, Nguyen HT, Kim JO, Yong CS, Nguyen CN.
    Drug Dev Ind Pharm; 2017 Dec 01; 43(12):1952-1962. PubMed ID: 28724314
    [Abstract] [Full Text] [Related]

  • 18. A novel oleanolic acid-loaded PLGA-TPGS nanoparticle for liver cancer treatment.
    Bao X, Gao M, Xu H, Liu KX, Zhang CH, Jiang N, Chu QC, Guan X, Tian Y.
    Drug Dev Ind Pharm; 2015 Dec 01; 41(7):1193-203. PubMed ID: 25026246
    [Abstract] [Full Text] [Related]

  • 19. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
    Zhang X, Li J, Yan M.
    Drug Dev Ind Pharm; 2016 Oct 01; 42(10):1590-9. PubMed ID: 26942448
    [Abstract] [Full Text] [Related]

  • 20. Efficient Delivery of DOX to Nuclei of Hepatic Carcinoma Cells in the Subcutaneous Tumor Model Using pH-Sensitive Pullulan-DOX Conjugates.
    Li H, Cui Y, Sui J, Bian S, Sun Y, Liang J, Fan Y, Zhang X.
    ACS Appl Mater Interfaces; 2015 Jul 29; 7(29):15855-65. PubMed ID: 26140410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.